fda bpc 157 warning letter 2024 2025 The U.S. Food and Drug Administration is moving toward allowing compounding pharmacies to produce more than a dozen injectable peptides that were banned because of potentially significant safety risks, the New York US FDA Warning Letters: Considerations
Description
For people who are sensitive to medications, have complex medical histories, or simply prioritize avoiding side effects above all else, AOD 9604 tolerability profile is its strongest selling point

doing so may produce significant benefits for these patients

You cant overdose, and theres no toxicity threshold
Do not think in terms of "days" as abstract concepts